Last quarter (Q ), Nymox Pharmaceutical's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Nymox Pharmaceutical's net income was $―. See Nymox Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 5.00K	$ 116.00K	$ 299.00K
Cost of Revenue	-	-	-	$ 4.00K	$ 58.00K	$ 138.00K
Gross Profit	-	-	-	$ 1.00K	$ 58.00K	$ 161.00K
Operating Expense	$ 8.33M	$ 6.62M	$ 12.50M	$ 11.72M	$ 13.38M	$ 10.80M
Operating Income	$ -8.33M	$ -6.62M	$ -12.50M	$ -11.72M	$ -13.32M	$ -10.64M
Net Non Operating Interest Income Expense	$ -23.00K	$ 6.00K	$ 6.00K	$ -15.00K	$ 175.00K	$ 54.00K
Other Income Expense	$ 3.12M	$ 6.45M	$ 12.58M	$ -3.00K	$ -12.00K	$ -7.00K
Pretax Income	$ -5.24M	$ -13.07M	$ -25.07M	$ -11.74M	$ -13.16M	$ -10.59M
Tax Provision	-	-	-	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -5.24M	$ -13.07M	$ -25.07M	$ -11.74M	$ -13.16M	$ -10.59M
Basic EPS	$ -0.07	$ -0.07	$ -0.15	$ -0.16	$ -0.19	$ -0.18
Diluted EPS	$ -0.07	$ -0.07	-	$ -0.16	$ -0.19	$ -0.18
Basic Average Shares	$ 267.71M	$ 89.38M	$ 81.98M	$ 73.82M	$ 68.84M	$ 60.47M
Diluted Average Shares	$ 282.73M	$ 89.38M	-	$ 73.82M	$ 68.84M	$ 60.47M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	$ 6.00K	-	-	-	-	-
Total Expenses	$ 8.33M	$ 6.62M	$ 12.50M	$ 11.72M	$ 13.44M	$ 10.94M
Net Income From Continuing And Discontinued Operation	$ -5.24M	$ -13.07M	$ -25.07M	$ -11.74M	$ -13.16M	$ -10.59M
Normalized Income	$ -5.24M	-	-	$ -11.73M	$ -13.15M	$ -10.59M
Interest Expense	$ 12.00K	-	-	$ 42.00K	$ 38.00K	$ 18.00K
EBIT	$ -8.33M	$ -13.07M	$ -25.08M	$ -11.70M	$ -13.12M	$ -10.58M
EBITDA	$ -8.14M	$ -13.10M	-	$ -11.43M	$ -12.56M	$ -10.57M

Currency in USD

Nymox Pharmaceutical Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing